Lyell Immunopharma Files 8-K with Financials

Ticker: LYEL · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1806952

Lyell Immunopharma, Inc. 8-K Filing Summary
FieldDetail
CompanyLyell Immunopharma, Inc. (LYEL)
Form Type8-K
Filed DateJun 26, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, regulation-fd

TL;DR

Lyell Immunopharma dropped an 8-K on 6/26 - check financials and other events.

AI Summary

Lyell Immunopharma, Inc. filed an 8-K on June 26, 2024, reporting on various events. The filing includes financial statements and exhibits, and is categorized under Regulation FD Disclosure and Other Events. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.

Why It Matters

This 8-K filing provides an update on Lyell Immunopharma's corporate activities and financial reporting, which is crucial for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting routine corporate events and financial statements, not indicating any immediate significant risks.

Key Numbers

  • 001-40502 — SEC File Number (Identifies the company's filing with the SEC.)
  • 83-1300510 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • Lyell Immunopharma, Inc. (company) — Registrant
  • June 26, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • South San Francisco, California (location) — Address of Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing for Lyell Immunopharma, Inc.?

The primary purpose is to report on various events, including Regulation FD Disclosures, Other Events, and to file Financial Statements and Exhibits, as of June 26, 2024.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 26, 2024.

In which state is Lyell Immunopharma, Inc. incorporated?

Lyell Immunopharma, Inc. is incorporated in Delaware.

What is the business address of Lyell Immunopharma, Inc.?

The business address of Lyell Immunopharma, Inc. is 201 Haskins Way, South San Francisco, California, 94080.

What is the SEC file number for Lyell Immunopharma, Inc.?

The SEC file number for Lyell Immunopharma, Inc. is 001-40502.

Filing Stats: 1,034 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2024-06-26 08:32:21

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LYEL The Nasdaq

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No 99.1 Press Release, dated June 26, 2024, titled "Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology." 99.2 Lyell Immunopharma, Inc. Presentation dated June 2024 104.1 Cover Page Interactive Data File, formatted in inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date: June 26, 2024 By: /s/ Matthew Lang Matthew Lang Chief Business Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.